1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of reducing specific activity of [(177)Lu]-DKFZ-PSMA617 on uptake in the tumor, salivary gland and kidney
    Meeting Abstract

    Kalidindi, T. M.; Lee, S. G.; Punzalan, B.; Veach, D.; Jou, K.; Chakraborty, G.; Tagawa, S.; Bander, N.; Lewis, J.; Larson, S.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Delta-like ligand 3 (DLL3) is a novel target for molecular imaging of neuroendocrine prostate cancer
    Meeting Abstract

    Korsen, J.; Kalidindi, T.; Khitrov, S.; Khuram, H.; Piorier, J.; Rudin, C.; Chen, Y.; Pillarsetty, N. V. K.; Lewis, J.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Pretargeted theranostic radioimmunotherapy with a Cu-64/Cu-67 isotopologue pair
    Meeting Abstract

    Keinaenen, O.; Fung, K.; Brennan, J.; Zia, N.; Harris, M.; Van Dam, E.; Biggin, C.; Hedt, A.; Stoner, J.; Donnelly, P.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Multicycle pretargeted radioimmunotherapy using 177(Lu) for intraperitoneal GPA33-expressing colorectal xenografts
    Meeting Abstract

    Chandler, C.; Cheal, S.; Nash, G.; Cercek, A.; Punzalan, B.; Veach, D.; Xu, H.; Guo, H. F.; Larson, S.; Cheung, N. K.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Pretargeted radioimmunotherapy using 225(Ac) for intraperitoneal GPA33-expressing colorectal xenografts
    Meeting Abstract

    Chandler, C.; Cheal, S.; Nash, G.; Cercek, A.; McDevitt, M.; Xu, H.; Guo, H. F.; Cheung, N. K.; Larson, S.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Pretargeted alpha radioimmunotherapy (DOTA-PRIT) for HER2-expressing human gastric cancer: A theranostic approach using 111(In)/225(Ac)-radiohapten
    Meeting Abstract

    Cheal, S.; McDevitt, M.; Burnes Vargas, D.; Veach, D.; Punzalan, B.; Xu, H.; Guo, H. F.; Ouerfelli, O.; Cheung, N. K.; Larson, S.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • (225)Ac-alpha pretargeted radioimmunotherapy (DOTA-PRIT) of human colorectal cancer: Achieving 100% complete responses with single-cycle targeting of 2 distinct antigens, HER2 and GPA33
    Meeting Abstract

    Cheal, S.; McDevitt, M.; Burnes Vargas, D.; Veach, D.; Punzalan, B.; Xu, H.; Guo, H. F.; Ouerfelli, O.; Larson, S.; Cheung, N. K.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC)
    Meeting Abstract

    Veeraraghavan, J.; Gutierrez, C.; De Angelis, C.; Wang, T.; Pascual, T.; Weigelt, B.; Galvan, P.; Rexer, B. N.; Forero-Torres, A.; Wolff, A. C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save